The Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF) -2020report provides an overview of the disease, epidemiology and global market trends for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. According to DelveInsight, Global Anticoagulants (VTE & AF) Therapeutics Market was around $11.4 billion in 2015 and is estimated to reach $17.2 billion by 2020 growing at a CAGR of 8.59% from 2015 to 2020.
Coagulation is an important phenomenon of body to stop external bleeding but when clots are formed in blood vessels, it can be lethal. Blood clots in arteries can lead to heart attack and when formed in the blood vessels of brain can lead to stroke. Thus, anticoagulants are used to prevent the formation of blood clots in the body. Anticoagulants are proved to be a beneficial medication for the treatment of Atrial fibrillation, Deep Vein Thrombosis, Pulmonary Embolism and Stroke. Globally the overall incidence for Venous Thromboembolism (VTE) and Atrial fibrillation (AF) is increasing at a higher rate. For VTE, there are approximately 1 million cases in the United States each year, many of which represent recurrent disease and AF affects approximately 3 million patients in the US, and over 6.7 million in the US and Europe combined.
Key Coverage and Benefits:
• The report will help in developing business strategies by understanding the trends shaping and driving the global Venous Thromboembolism (VTE) market.
• Identifying patient populations in the global Venous Thromboembolism (VTE) market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Venous Thromboembolism (VTE) therapeutics in each of the markets covered.
• To understand the future market competition in the global Venous Thromboembolism (VTE) therapeutics market and Insightful review of the key market drivers and barriers.
Scope of the Report:
• Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
• Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2015-2020.
• It also provides Venous Thromboembolism (VTE) for United States, EU5 and Japan from 2015 and forecasted Market to 2020.
'
Table of Contents
Executive Summary
Market Share of Anticoagulants in 2015 and 2020
Worldwide Market Share of Anticoagulants in 2015
Worldwide Market Share of Anticoagulants in 2020
Chapter 1 Anticoagulants Introduction
Warfarin
Low Molecular Weight Heparins
New Oral Anticoagulants (NOAC)
Chapter 2 Venous Thromboembolism
Disease Overview
Epidemiology of Venous Thromboembolism
Treatment Landscape
Treatment Algorithm
Treatment Goals
Treatment Details
Chapter 3 Atrial Fibrillation
Disease Overview
Epidemiology of Atrial Fibrillation
Treatment Landscape
Treatment Algorithm
Treatment Goals
Treatment Details
Chapter 4 Key Marketed Anticoagulants
Novel Oral Anticoagulants Comparison
Reversal Agents (Antidotes)
Chapter 5 Anticoagulants Market Assessment
Key Findings
Global Anticoagulants Sales
Global Anticoagulants Market by Drugs
Global Anticoagulants Market Share (%)
Global Anticoagulants Market Sales by Atrial Fibrillation (AF)
Global Anticoagulants Market Share (%) in Atrial Fibrillation
Global Anticoagulants Market Sales by Venous Thromboembolism
Global Anticoagulants Market Share (%) in Venous Thromboembolism
Chapter 6 United States Anticoagulants Market Assessment
Key Findings
United States Anticoagulants Market
United States Anticoagulants Market Share (%)
United States Anticoagulants Market Sales by Atrial Fibrillation
United States Anticoagulants Market Share (%) in Atrial Fibrillation
United States Anticoagulants Market Sales by Venous Thromboembolism
United States Anticoagulants Market Share (%) in Venous
Thromboembolism
Chapter 8 Europe 5 Anticoagulants Market Assessment
Key Findings
Europe 5 Anticoagulants Market
Europe 5 Anticoagulants Market Share (%)
Europe 5 Anticoagulants Market Sales by Atrial Fibrillation
Europe 5 Anticoagulants Market Share (%) in Atrial Fibrillation
Europe 5 Anticoagulants Market Sales by Venous Thromboembolism
Europe 5 Anticoagulants Market Share (%) in Venous Thromboembolism
Chapter 10 Japan Anticoagulants Market Assessment
Key Findings
Japan Anticoagulants Market
Japan Anticoagulants Market Share (%)
Japan Anticoagulants Market Sales by Atrial Fibrillation
Japan Anticoagulants Market Share (%) in Atrial Fibrillation
Japan Anticoagulants Market Sales by Venous Thromboembolism
Japan Anticoagulants Market Share (%) in Venous Thromboembolism
Chapter 12 Xarelto (rivaroxaban) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Xarelto
Safety of Xarelto
Side effects of Drugs
Cost of Therapy
Global Drug Sales
Xarelto Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Xarelto Historical Sales and Forecasted Sales (2011-2020) by AF
Xarelto Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trials Information
SWOT Analysis of Xarelto
Chapter 13 Pradaxa (dabigatran etexilate mesylate) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Pradaxa
Safety of Pradaxa
Side effects of Drugs
Cost of Therapy
Global Drug Sales
Pradaxa Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Pradaxa Historical Sales and Forecasted Sales (2011-2020) by AF
Pradaxa Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trial Information
SWOT Analysis of Pradaxa
Chapter 15 Eliquis(Apixaban) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy and Safety of Eliquis
Side effects of Eliquis
Cost of Therapy
Global Drug Sales
Eliquis Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Eliquis Historical Sales and Forecasted Sales (2011-2020) by AF
Eliquis Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trial Information
SWOT Analysis of Eliquis
Chapter 16 Savaysa (edoxaban tosylate) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Savaysa
Safety of Savaysa
Side Effects of Savaysa
Cost of Therapy
Global Drug Sales
Savaysa Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Savaysa Historical Sales and Forecasted Sales (2011-2020) by AF
Savaysa Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trial Information
SWOT Analysis of Savaysa
Chapter 18 Lovenox (enoxaparin) Drug Profile
Product Profile
Advantages & Disadvantages
Safety and Efficacy of Lovenox
Side effects of Lovenox
Cost of Therapy
Global Drug Sales
Lovenox Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication (20%)
Lovenox Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trial Information
SWOT Analysis of Lovenox
Chapter 19 Fraxiparine
Product Profile
Advantages & Disadvantages
Safety and Efficacy of Fraxiparine
Side effects of Drugs
Cost of Therapy
Global Drug Sales
Fraxiparine Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Fraxiparine Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trials Information
SWOT Analysis of Fraxiparine
Chapter 20 Arixtra (Fondaparinux) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Arixtra
Safety of Arixtra
Side effects of Drugs
Cost of Therapy
Global Drug Sales
Arixtra Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Arixtra Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trial Information
SWOT Analysis of Arixtra
Chapter 21 Betrixaban Drug Profile
Product Profile
Advantages & Disadvantages
Safety and Efficacy
Side effects of Drugs
Expected Cost of Therapy
Global Drug Sales
Betrixaban Forecasted Sales (2011-2020)
Global Drug Sales by indication
Betrixaban Historical Sales and Forecasted Sales (2011-2020) by VTE
Clinical Trials Information
Chapter 22 Market Drivers and Constraints
Factors Driving the Market Growth
Factors Constraining the Market Growth
Consulting Services
Disclaimer
About DelveInsight
List of Tables
Table 1: Key Marketed Anticoagulants
Table 2: Comparison of NOACs & Warfarin
Table 1: Global Anticoagulants Sales- 2015-2020 (USD MM)
Table 2: Global Anticoagulants Sales by Drugs- 2011-2020 (USD MM)
Table 3: Global Anticoagulants Sales by Drugs- 2015-2020 (USD MM)
Table 4: Global Anticoagulants Sales in Atrial Fibrillation 2011-2020 (USD MM)
Table 5: Global Anticoagulants Sales in Atrial Fibrillation – 2015-2020 (USD MM)
Table 6: Global Anticoagulants Sales in Venous Thromboembolism 2011-2020 (USD MM)
Table 7: Global Anticoagulants Sales in Venous Thromboembolism - 2015-2020 (USD MM)
Table 8: US Anticoagulants Sales- 2011-2020 (USD MM)
Table 9: US Anticoagulants Sales- 2015-2020 (USD MM)
Table 10: US Anticoagulants Sales in Atrial Fibrillation 2011-2020 (USD MM)
Table 11: US Anticoagulants Sales in Atrial Fibrillation - 2015-2020 (USD MM)
Table 12: US Anticoagulants Sales in Venous Thromboembolism 2011-2020 (USD MM)
Table 13: US Anticoagulants Sales in Venous Thromboembolism - 2015-2020 (USD MM)
Table 14: EU5 Anticoagulants Sales- 2011-2020 (USD MM)
Table 15: EU5 Anticoagulants Sales- 2015-2020 (USD MM)
Table 16: EU5 Anticoagulants Sales in Atrial Fibrillation 2011-2020 (USD MM)
Table 17: EU5 Anticoagulants Sales in Atrial Fibrillation - 2015-2020 (USD MM)
Table 18: EU5 Anticoagulants Sales in Venous Thromboembolism 2011-2020 (USD MM)
Table 19: EU5 Anticoagulants Sales in Venous Thromboembolism – 2015-2020 (USD MM)
Table 20: Japan Anticoagulants Sales- 2011-2020 (USD MM)
Table 21: Japan Anticoagulants Sales- 2015-2020 (USD MM)
Table 22: Japan Anticoagulants Sales in Atrial Fibrillation 2011-2020 (USD MM)
Table 23: Japan Anticoagulants Sales in Atrial Fibrillation - 2015-2020 (USD MM)
Table 24: Japan Anticoagulants Sales in Venous Thromboembolism 2011-2020 (USD MM)
Table 25: Japan Anticoagulants Sales in Venous Thromboembolism - 2015-2020 (USD MM)
Table 26: Xarelto Historical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 29: Xarelto Sales by Atrial Fibrillation (AF) (USD MM)
Table 27: Xarelto Sales by Venous Thromboembolism (VTE) (USD MM)
Table 29: Xarelto, Clinical Trials by Zone, 2016
Table 30: Pradaxa Historical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 33:Pradaxa Sales by Atrial Fibrillation (AF) (USD MM)
Table 34: Pradaxa Sales by Venous Thromboembolism (VTE) (USD MM)
Table 33: Pradaxa, Clinical Trials by Zone, 2016
Table 34: Eliquis Historical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 37:Eliquis Sales by Atrial Fibrillation (AF) (USD MM)
Table 35: Eliquis Sales by Venous Thromboembolism (VTE) (USD MM)
Table 37: Eliquis, Clinical Trials by Zone, 2016
Table 38:Savaysa Historical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 41:SavaysaSales by Atrial Fibrillation (AF) (USD MM)
Table 39: SavaysaSales by Venous Thromboembolism (VTE) (USD MM)
Table 41: Savaysa, Clinical Trials by Zone, 2016
Table 42: LovenoxHistorical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 43: LovenoxSales by Venous Thromboembolism (VTE) (USD MM)
Table 44:Lovenox, Clinical Trials by Zone, 2016
Table 45:FraxiparineHistorical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 46: FraxiparineSales by Venous Thromboembolism (VTE) (USD MM)
Table 47:Fraxiparine, Clinical Trials by Zone, 2016
Table 48: ArixtraHistorical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 49: ArixtraSales by Venous Thromboembolism (VTE) (USD MM)
Table 50:Arixtra, Clinical Trials by Zone, 2016
Table 51:BetrixabanForecasted Sales (2011-2020)(USD MM)
Table 52: BetrixabanSales by Venous Thromboembolism (VTE) (USD MM)
Table 53:Betrixaban, Clinical Trials by Zone, 2016
List of Figures
Figure 1: Global Anticoagulants Sales- 2015-2020
Figure 2: Global Anticoagulants Sales by Drugs- 2011-2020
Figure 3: Global Anticoagulants Market Share by Drugs (%)- 2011-2020
Figure 4: Global Anticoagulants Sales in Atrial Fibrillation- 2011-2020
Figure 5: Global Anticoagulants Market Share (%) in Atrial Fibrillation - 2011-2020
Figure 6: Global Anticoagulants Sales in Venous Thromboembolism- 2011-2020
Figure 7: Global Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
Figure 8: US Anticoagulants Sales- 2011-2020
Figure 9: US Anticoagulants Market Share (%)- 2011-2020
Figure 10: US Anticoagulants Sales in Atrial Fibrillation- 2011-2020
Figure 11: US Anticoagulants Market Share (%) in Atrial Fibrillation - 2011-2020
Figure 12: US Anticoagulants Sales in Venous Thromboembolism- 2011-2020
Figure 13: US Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
Figure 14: EU5 Anticoagulants Sales- 2011-2020
Figure 15: EU5 Anticoagulants Market Share (%)- 2011-2020
Figure 16: EU5 Anticoagulants Sales in Atrial Fibrillation- 2011-2020
Figure 17: EU5 Anticoagulants Market Share (%) in Atrial Fibrillation - 2011-2020
Figure 18: EU5 Anticoagulants Sales in Venous Thromboembolism- 2011-2020
Figure 19: EU5 Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
Figure 20: Japan Anticoagulants Sales- 2011-2020
Figure 21: Japan Anticoagulants Market Share (%)- 2011-2020
Figure 22: Japan Anticoagulants Sales in Atrial Fibrillation- 2011-2020
Figure 23: Japan Anticoagulants Market Share (%) in Atrial Fibrillation - 2011-2020
Figure 24: Japan Anticoagulants Sales in Venous Thromboembolism- 2011-2020
Figure 25: Japan Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
Figure 26: Xarelto Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 27: Xarelto Sales by Atrial Fibrillation (AF)(USD MM)
Figure 27: Xarelto Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 29: Xarelto, Clinical Trials by Zone (%), 2016
Figure 30: Pradaxa Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 31: PradaxaSales by Atrial Fibrillation (AF)(USD MM)
Figure 32: Pradaxa Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 33: Pradaxa, Clinical Trials by Zone (%), 2016
Figure 34: Eliquis Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 35: EliquisSales by Atrial Fibrillation (AF)(USD MM)
Figure 35: Eliquis Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 37: Eliquis, Clinical Trials by Zone (%), 2016
Figure 38: SavaysaHistorical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 39: SavaysaSales by Atrial Fibrillation (AF)(USD MM)
Figure 39: Savaysa Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 41: Savaysa, Clinical Trials by Zone (%), 2016
Figure 42: Lovenox Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 43: Lovenox Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 44: Lovenox, Clinical Trials by Zone (%), 2016
Figure 45: Fraxiparine Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 46: Fraxiparine Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 47: Fraxiparine, Clinical Trials by Zone (%), 2016
Figure 48: ArixtraHistorical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 49: Arixtra Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 50: Arixtra, Clinical Trials by Zone (%), 2016
Figure 51: BetrixabanForecasted Sales (2011-2020) (USD MM)
Figure 52: Betrixaban Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 53: Betrixaban, Clinical Trials by Zone (%), 2016
Bayer
Janssen Pharmaceutica
Boehringer Ingelheim
Bristol-Myers Squib
Daiichi Sankyo
Sanofi-Aventis
Glaxosmithkline
Aspen Pharmaceuticals
Portola Pharmaceuticals
